Browsing Barts Cancer Institute by Subject "6.1 Pharmaceuticals"
Now showing items 1-2 of 2
-
Abstract 5591: Circulating tumor DNA for recurrence prediction and efficacy analysis in the ICONIC trial of peri-operative FLOT and avelumab (PD-L1) in localized esophago-gastric adenocarcinoma
(American Association for Cancer Research (AACR), 2023-04-04) -
Phase 2 study to evaluate the novel mitochondrial PRX3 inhibitor, RSO-021, as an intrapleural monotherapy and in combination with IV paclitaxel in patients with malignant pleural effusion due to mesothelioma or another advanced solid tumor.
(American Society of Clinical Oncology (ASCO), 2024-05-29)